Conventional Synthetic DMARD

DRUG2 trials

Sponsors

SetPoint Medical Corporation, SecondWave Systems Inc.

Conditions

Rheumatoid ArthritisRheumatoid Arthritis (RA)

Phase 3

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruitingNCT04539964

SetPoint Medical CorporationRheumatoid Arthritis

Start: 2021-01-11End: 2027-10-01Updated: 2026-02-10

Unknown Phase

At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]

RecruitingNCT07163221

SecondWave Systems Inc.Rheumatoid Arthritis (RA)

Start: 2025-11-03End: 2026-11-01Target: 60Updated: 2026-02-10

Related Papers

Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial.

2025-12-22

Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study.

2024-03-1313 citations

GLIOMA-05 A NOVEL CONCEPT FOR TREATMENT OF GLIOBLASTOMA: VAGUS NERVE ELECTRICAL STIMULATION FOR SUPPRESSION OF CYTOKINE (IL-6) SIGNALING

Neuro-Oncology Advances2023-10-311 citations